Doctors are convinced that Truxima, the first rituximab biosimilar approved by the FDA, is as effective as rituximab; European experience with the biosimilar over the last 2 years has also revealed no problems with unexpected side effects. However, cost will be a factor in determining whether doctors in the United States prescribe Truxima instead of rituximab.
http://bit.ly/2DZaB9N
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.